A Phase IIb, Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Finding Study of MK3207 in the Treatment of Acute Migraine.

Trial Profile

A Phase IIb, Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Finding Study of MK3207 in the Treatment of Acute Migraine.

Completed
Phase of Trial: Phase II

Latest Information Update: 09 May 2014

At a glance

  • Drugs MK 3207 (Primary)
  • Indications Migraine
  • Focus Therapeutic Use
  • Acronyms COMPLETED
  • Sponsors Merck & Co; Merck Sharp & Dohme
  • Most Recent Events

    • 28 Apr 2012 Planned number of patients changed from 522 to 685 as reported by European Clinical Trials Database record.
    • 28 Apr 2012 Additional trial locations added as reported by European Clinical Trials Database record.
    • 24 Feb 2009 Actual end date changed from 1 Jan 2009 to 1 Feb 2009 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top